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Abstract: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome editing has
become a standard method in molecular biology, for the establishment of genetically modified cellular
and animal models, for the identification and validation of drug targets in animals, and is heavily
tested for use in gene therapy of humans. While the efficiency of CRISPR mediated gene targeting
is much higher than of classical targeted mutagenesis, the efficiency of CRISPR genome editing to
introduce defined changes into the genome is still low. Overcoming this problem will have a great
impact on the use of CRISPR genome editing in academic and industrial research and the clinic.
This review will present efforts to achieve this goal by small molecules, which modify the DNA repair
mechanisms to facilitate the precise alteration of the genome.
Keywords: CRISPR efficiency; low molecular weight compounds; homology directed repair
1. Introduction
The ability to manipulate DNA sequences by molecular biology techniques had a fundamental
impact on experimental biology. Furthermore, the work of Herbert Boyer and Stanley Cohen on
restriction enzymes paved the way for the establishment of Biotechnology Industries [1].
The most commonly used tools in DNA manipulation, including restriction enzymes and
recombinases, are derived from defense mechanisms that prokaryotes have developed to fight viral
infections, or from viral mechanisms of replication and survival to host defense mechanisms. Therefore,
it is not surprising that the development of tools for in cellular DNA engineering of prokaryotes and
eukaryotes has exploited similar bacterial or viral mechanisms.
The lambda Red recombination system from the bacteriophage lambda is currently the most
efficient system of DNA engineering in prokaryotes [2]. This system exploits the ability of Redβ to
anneal a single strand DNA donor to the single-strand DNA exposed during bacterial or plasmid DNA
replication. The lambda Red recombination system is very dependent on the DNA replication status of
the target locus, the electroporation, the stability of the incoming DNA donor and often requires the
antibiotic selection to isolate a recombination event. A similar mechanism based on endogenous DNA
annealing at the replication fork or the transcription bubble has been developed in lower eukaryotes
such as the yeast Saccharomyces cerevisiae allowing efficient DNA engineering of these organisms.
Unfortunately, higher eukaryotes are not prone to DNA manipulation by DNA annealing, probably
due to their chromatin structure and their DNA repair system. Interestingly, Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR) defense mechanisms exploiting Cas9 endonucleases
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and targeting RNAs are not naturally recombinogenic in bacteria and are not good tools for DNA
engineering in bacterial cells without providing exogenous recombination systems. This is in contrast
to the extended use of CRISPR/Cas9 derived tools for DNA engineering in eukaryotes. Most of the
CRISPR/Cas9 tools are not directly inserting the desired modification but they are just generating repair
intermediates like DNA Double-Strand Breaks (DSBs) or single-strand nicks, that promote exogenous
DNA capture or random insertions or deletions (indels).
Thus, after introducing a CRISPR/Cas9-targeted DSB, which can be highly toxic to cells if not
repaired, the cell’s DNA repair machinery is activated to join the loose DNA ends and determines the
outcome of an editing event. There are two major repair categories: Homology Directed Repair (HDR)
and End-Joining (EJ). The latter can be further divided into Non-Homologous End-Joining (NHEJ) and
alternative End-Joining (a-EJ).
The work of Maria Jasin’s group and collaborators indicated for the first time in 1994 that HDR is
a major DSB repair pathway in mammalian cells, paving the way to the utilization of rare DNA-cutters,
like CRISPR/Cas9, to promote HDR in mammalian cells [3]. Subsequent studies have also exploited
NHEJ to promote loss of function editing by indels and integration at a DSB with rare DNA-cutters [4].
CRISPR mediated HDR is currently the most utilized method to facilitate targeted gene integration.
However, the low efficiency of HDR in most eukaryotic cells is a major limitation. The activity
of different DNA repair pathways at the DSB results in mixed editing outcomes. The deletions or
insertions from NHEJ or a-EJ repair are mostly undesired in particular for therapeutically gene editing
approaches. Finding ways to increase HDR efficiency, therefore, is a major goal in CRISPR genome
editing research. This review describes recent approaches that have been made to improve HDR
efficiency by small molecules. To set the stage main DSB repair pathways in mammalian cells will
be introduced together with the key factors involved (Figure 1). A thorough depiction of DSB repair
pathways is beyond the scope of this review, and for a more comprehensive overview, we recommend
the review by Scully et al. (2019) [5].
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Figure 1. Major mammalian DNA damage repair pathways at Cas9-induced DSBs together with small 
molecules and one peptide (i53) reported to increase knock-in efficiencies. Shown are the three major 
repair pathways after a CRISPR/Cas9-induced DNA double-strand break. (a) Depicted is a 
Cas9/sgRNA complex cleaving DNA. (b) During Non-Homologous End-Joining (NHEJ) Ku70/Ku80 
protect free DNA-ends from end resection. DNA-Protein-Kinase catalytical subunit (DNA-PKcs) 
phosphorylates different DNA repair enzymes. Ends are processed through Artemis, Polymerase Mu 
(POLM) and Polymerase Lambda (POLL) and ligated by the Ligase IV, X-Ray Repair Cross-
Complementing Protein and 4 XRCC4-like Factor (LIG4-XRCC4-XLF) complex. (c,d) Breast Cancer 
Type 1 (BRCA1) antagonizes p53-Binding Protein 1 (53BP1) and enables end resection mediated by 
CtBP-interacting protein (CtIP) and the MRN complex Meiotic Recombination 11 (MRE11), RAD50, 
and Nijmegen Breakage Syndrome 1 (NBS1) necessary for alternative End-Joining (a-EJ) and 
Homology Directed Repair (HDR). The Kinases Ataxia Telangiectasia Mutated (ATM) and ATM-
Rad3- related (ATR) function as damage sensors and activate different repair enzymes. (c) In a-EJ 
extensive end resection is prevented through Poly [ADP-ribose] Polymerase 1 (PARP1). After 
annealing of short homologies, X-Ray Repair Cross Complementing 1 (XRCC1) or Flap Endonuclease 
1 (FEN1) cleave 5′-flaps and Polymerase Theta (POLQ) performs gap-fillings. Ligase I (LIG1) or Ligase 
III alpha-XRCC1 (LIGA-XRCC1) ligate DNA ends. (d) HDR requires extensive end resection mediated 
by Exonuclease 1 (EXO1) or Bloom Helicase and DNA2 Helicase/Nuclease (BLM-DNA2). Replication 
Protein A (RPA) binding of single-stranded DNA prevents the formation of secondary structures. 
RPA is replaced by RAD51 with the help of Breast Cancer type 2 (BRCA2) and Partner and Localizer 
of BRCA2 (BRAC2-PALB2). RAD51 promotes homology donor search and base pairing. (e) Cell cycle 
dependency of DNA repair pathways: NHEJ is active through all cell cycle phases. Pathways 
requiring end resection are mainly active in the S-G2 phase. 
2. Non-Homologous End-Joining Repair of Double-Strand Breaks 
NHEJ is the predominant pathway to repair DSBs in mammalian cells. Broken ends can be 
repaired using various forms of end processing. In the initial recognition step, Ku70 and Ku80 bind 
sequence independently to lose DNA ends and form the Ku heterodimer. The complex forms a ring-
shape, which keeps the free DNA ends in proximity of each other [6] and prevents end resection. The 
Ku complex recruits the DNA-Protein Kinase catalytical subunit (DNA-PKcs), which belongs to the 
Figure 1. Major mammalian DNA damage repair pathways at Cas9-induced DSBs together with small
molecules and one peptide (i53) reported to increase knock-in efficiencies. Shown are the three major
repair pathways after a CRISPR/Cas9-induced DNA double-strand break. (a) Depicted is a Cas9/sgRNA
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complex cleaving DNA. (b) During Non-Homologous End-Joining (NHEJ) Ku70/Ku80 protect free
DNA-ends from end resection. DNA-Protein-Kinase catalytical subunit (DNA-PKcs) phosphorylates
different DNA repair enzymes. Ends are processed through Artemis, Polymerase Mu (POLM) and
Polymerase Lambda (POLL) and ligated by the Ligase IV, X-Ray Repair Cross-Complementing Protein
and 4 XRCC4-like Factor (LIG4-XRCC4-XLF) complex. (c,d) Breast Cancer Type 1 (BRCA1) antagonizes
p53-Binding Protein 1 (53BP1) and enables end resection mediated by CtBP-interacting protein (CtIP)
and the MRN complex Meiotic Recombination 11 (MRE11), RAD50, and Nijmegen Breakage Syndrome
1 (NBS1) necessary for alternative End-Joining (a-EJ) and Homology Directed Repair (HDR). The
Kinases Ataxia Telangiectasia Mutated (ATM) and ATM-Rad3- related (ATR) function as damage
sensors and activate different repair enzymes. (c) In a-EJ extensive end resection is prevented through
Poly [ADP-ribose] Polymerase 1 (PARP1). After annealing of short homologies, X-Ray Repair Cross
Complementing 1 (XRCC1) or Flap Endonuclease 1 (FEN1) cleave 5′-flaps and Polymerase Theta
(POLQ) performs gap-fillings. Ligase I (LIG1) or Ligase III alpha-XRCC1 (LIGA-XRCC1) ligate DNA
ends. (d) HDR requires extensive end resection mediated by Exonuclease 1 (EXO1) or Bloom Helicase
and DNA2 Helicase/Nuclease (BLM-DNA2). Replication Protein A (RPA) binding of single-stranded
DNA prevents the formation of secondary structures. RPA is replaced by RAD51 with the help of
Breast Cancer type 2 (BRCA2) and Partner and Localizer of BRCA2 (BRAC2-PALB2). RAD51 promotes
homology donor search and base pairing. (e) Cell cycle dependency of DNA repair pathways: NHEJ
is active through all cell cycle phases. Pathways requiring end resection are mainly active in the
S-G2 phase.
2. Non-Homologous End-Joining Repair of Double-Strand Breaks
NHEJ is the predominant pathway to repair DSBs in mammalian cells. Broken ends can be repaired
using various forms of end processing. In the initial recognition step, Ku70 and Ku80 bind sequence
independently to lose DNA ends and form the Ku heterodimer. The complex forms a ring-shape, which
keeps the free DNA ends in proximity of each other [6] and prevents end resection. The Ku complex
recruits the DNA-Protein Kinase catalytical subunit (DNA-PKcs), which belongs to the PI3-Kinase
related Protein Kinases (PI3KK) family. DNA-PKcs auto-phosphorylates and phosphorylates factors
involved in NHEJ [7–9]. Autophosphorylation is required to make the DNA ends more accessible
to repair enzymes to facilitate end ligation [10]. If needed to facilitate ligation, the nuclease Artemis
processes incompatible ends [11]. Nucleotides are added in a template-dependent or -independent
manner by the polymerases Polymerase Mu (POLM) and Polymerase Lambda (POLL) [12]. Compatible
DNA ends are ligated by Ligase IV (LIG4), X-Ray Repair Cross-Complementing protein 4–XRCC4-like
Factor (XRCC4-XLF) complex [13,14]. NHEJ is commonly believed to introduce mutations such as
small insertions and deletions. However, it was shown that Ku-dependent end repair is in most cases
precise [15]. A review from 2014 [16] emphasizes that the DNA end structure and amount of end
processing needed for repairing the DSB, determine the precision of NHEJ. Brinkman and colleagues
suggest, that the precise NHEJ-mediated repair of naturally occurring DSBs, is not exemplary for
Cas9-induced DSBs [17] (Figure 1b).
3. Homology Directed Repair of Double-Strand Breaks
In contrast to NHEJ, HDR is inherently precise because it involves a homologous template
to repair the DSB. In dividing cells, the sister chromatid serves as the perfect undamaged repair
template. HDR requires extensive 5′–3′ end resection, resulting in single-stranded DNA (ssDNA)
overhangs. End resection is initiated by CtBP-interacting protein (CtIP), which activates the MRN
complex [18]. The MRN complex is formed by Meiotic Recombination 11 (MRE11), a 5′–3′exonuclease
and 3′-5′endonuclease, RAD50, an ABC ATPase, and Nijmegen breakage syndrome 1 (NBS1). NBS1
interacts with Ataxia–Telangiectasia Mutated (ATM) or ATM- and Rad3-related (ATR) protein kinases.
ATM and ATR are both phosphorylating proteins involved in cell cycle regulation and DNA repair.
Like DNA-PKcs, they belong to the PI3KK family. ATM senses mainly DSBs, while ATR senses
single-stranded DNA [19]. The initial end resection through MRN is followed by an extensive end
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resection through Exonuclease 1 (EXO1) or Bloom Helicase and DNA2 Helicase/Nuclease (BLM-DNA2)
and coating of 3′ ssDNA with Replication Protein A (RPA) [20]. These processes are thereafter followed
by RPA replacement with RAD51 loading through Breast Cancer Type 2 (BRCA2) with the help of Partner
and Localizer of BRCA2 (PALB2) and Breast Cancer Type 1 (BRCA1). Furthermore, RAD52 has been
shown to support RAD51 loading in an early phase of DSB repair [21]. The recombinase RAD51 together
with the ssDNA nucleoprotein filament enables homology donor search and base-pairing [22]. The HDR
process is finalized through either a mechanism called SDSA (Synthesis-dependent Strand Annealing)
or DSBR (Double-Strand Break Repair Pathway), including the model of dHJ (double-Holliday Junction)
intermediate [23] (Figure 1d).
4. Alternative End-Joining Repair of Double-Strand Breaks
Alternative End-Joining, also known as Microhomology-mediated end joining (MMEJ), shares
characteristics of both the NHEJ and HDR pathway. The process is independent of Ku proteins
as well as homologous repair templates but makes use of short homology regions in the genome
(micro-homologies) to anneal strands. It requires short end resection by the MRN complex and
CtIP [24]. To avoid extensive end resection Poly [ADP-ribose] Polymerase 1 (PARP1) interaction with
the MRN complex plays an important role in a-EJ [25]. Microhomologies of 5–20 bp in the resulting
3′ssDNA anneal to each other. Resulting flaps are removed by X-Ray Repair Cross Complementing
1 (XLF-XRCC1) or Flap Endonuclease 1 (FEN1) [26]. DNA Polymerase Theta (POLQ) performs the
filling of gaps [27] before the ends are ligated through Ligase I (LIG1) or the complex of Ligase III
alpha (LIG3A)/XRCC1 [28]. Repair of DSB via a-EJ characteristically results in deletions. It should
be noted that the intrinsically error-prone a-EJ pathway has been reported to show an only minor
contribution to DSB repair in somatic cells and to be more relevant in cancer cells with defects in DNA
repair pathways. Consequently, a-EJ was initially considered as a back-up to replace non-functional
NHEJ or HDR processes. Currently, the contribution of a-EJ in cells with no deficiency in NHEJ or
HDR is under investigation [29] (Figure 1c).
5. Double-Strand Break Repair Pathway Choice is Influenced by Cell Cycle Stage
The cell cycle stage is tightly linked to the regulation of end resection and thereby has an important
role in the DSB repair pathway choice. NHEJ minimizes the processing required to join ends and is
active throughout the cell cycle. HDR and a-EJ are initiated by end resection and are mainly active in the
S and G2 phases as they depend on Cyclin-dependent Kinase (CDK) phosphorylation of downstream
enzymes [24]. In the G1 phase, major mechanisms of end resection are suppressed. The two factors,
BRCA1 and p53-Binding Protein 1 (53BP1), regulate the balance between NHEJ and HDR pathways
throughout the cell cycle. In the G1 phase, phosphorylated 53BP1 binds to the DSB, prevents end
resection and promotes NHEJ. Furthermore, during G1 phase BRCA1-dependent recruitment of PALB2
and BRCA2, and consequently the HDR machinery, the DSB is anticipated in a 53BP1 independent
manner [30]. During the S/G2 phases, BRCA1 antagonizes the 53BP1 reaction and enables end resection,
thus paving the way for HDR and a-EJ [31] (Figure 1e).
6. Small Molecules to Improve Precise Genome Editing
Targeted gene modification often suffers from low efficiency. HDR and NHEJ are competitive
repair processes and different approaches to shift the balance towards HDR have been tested. In 2008,
Beumer and colleagues showed that repair of zinc-finger induced DSB is channeled towards HDR
in Drosophila melanogaster lines lacking Ligase IV, an important NHEJ factor [32]. As a result,
down-regulation of NHEJ by gene knock-out [33], gene-silencing with siRNA [34] or shRNA [35] as
well as low molecular weight compounds targeting involved molecules have been tested to indirectly
increase HDR efficiency. Directly increasing HDR has been sought by overexpression of key HDR
molecules [36], the fusion of them to Cas9 [37], or chemical enhancers of their activity. This review
focuses on low molecular weight compounds to improve precise genome editing. Advantages of
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pharmacologically channeling DSB repair pathway choice to HDR include easy application to cell lines,
reversibility, and fast mode of action. However, the availability of selective and potent inhibitors is
limited and an appropriate candidate for the desired target might not be commercially available. Broadly
used inhibitors show variable specificity, with some of them also inhibiting unintended targets [38].
Unwanted side-effects can be kept at a minimum by using the lowest possible concentration [39].
Subtle changes to the experimental design, such as donor design or treatment time-frame, can have
an impact on the results. Therefore, confirmation of results and complementation of insights by
independent studies is especially important for small molecule validation. Finally, pharmacological
inhibition of target molecules is often more time- and labor- efficient than genetic knockout [39].
In the following NHEJ inhibitors will be introduced first, followed by direct enhancers of the HDR
pathway. Cell-cycle modulators are discussed thereafter, before finally addressing inhibitors with
unknown mechanisms. Small molecules addressed in this review are summarized in Table 1. They are
shown with their functional target and observed effects in cell lines and animal models. It is further
distinguished between single strand (ss) and double-strand (ds) donors, as it has been shown that
repair by single-strand donors involves a different set of repair factors than repair by double-strand
donors [40,41].
Table 1. Summary of small molecules described during this review with suggested targets and
observed effects.
Small Molecule Target Observed Effects Sources
i53
Prevents interaction of
53BP1 with ubiquitylated
histones at DSBs
Increased HDR with ss and ds donor in
several cell lines [42]
STL127705
Inhibits interaction of Ku
proteins with DNA and
Ku-dependent PKcs
activation
Not tested [43]
NU7441 Inhibition of DNA-PKcs
Reduces NHEJ and increases HDR in
HEK293T cells using ss or ds donors
Minor increase in hiPSC with ds donor
[44,45]
KU-0060648 Inhibition of DNA-PKcs Reduces NHEJ and increases HDR inHEK293T cells using ss or ds donors [44]
NU7026 Inhibition of DNA-PKcs
Increased KI with ss donor after Cas9
induced DSB or double nicking or Cpf1
induced DSB in hiPSC
No effect in mouse embryonic stem cells or
in mouse zygotes with ds donor
[34,46–48]
M3814 Inhibition of DNA-PKcs Increased KI in hiPSC and K562 cells withss donor using Cas9 or Cpf1 [33]
VE-822 Inhibition of ATR Increases HDR in hiPSC with ss or ds donorin combination with Cpf1 [49]
SCR7 Inhibitor of Ligase IV
Decreased NHEJ repair of an
extrachromosomal reporter system in
HeLa cells
Increased HDR in several cell lines with ds
donor or ss donor
Increased HDR in mice with ss donor
No HDR increase in rabbits with ds donor
Increased HDR in rats with ds donor
No HDR increase for an extrachromosomal
reporter in H1 cells
Inconsistent effects on HDR efficiency in
fetal porcine fibroblasts
[35,50–58]
RS-1
Enhances RAD51
binding to ssDNA after
end-resection
Increased HDR in cell lines and rabbit
embryos with ds donor
Increased HDR in bovine embryos with
ss donor
[58–61]
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Table 1. Cont.
Small Molecule Target Observed Effects Sources
Aphidicolin G1/S blocker HDR promoting effect in HEK293T andneonatal fibroblasts with ss donor [62]
Mimosin,
thymidine,
hydroxy urea
G1/S blocker
Increased HDR in neonatal fibroblasts with
ss donor
Decreased HDR in HEK293T cells with
ss donor
[62]
Nocodazole G2/M blocker
HDR promoting effect in HEK293T cells
with ss or ds donor
No HDR increase in neonatal fibroblasts or
human ESC using ss donor
Increased HDR in hPSC with ds donor
[57,62]
ABT-751 G2/M blocker Increased HDR in hPSC with ds donor [57]
XL413 G1/S blocker
Increased HDR in K562 cells and T cells
with ss or ds donor
Increase in HSPCs with ss donor (ds
not tested)
Additionally tested cell lines showed either
varying or no effects
[41]
L755507 β3-adrenergic receptoragonist
Increase in HDR in several cell lines with ss
and ds donors [55,63]
Brefeldin A
Inhibition of intracellular
transport from ER to
Golgi
Increase in HDR in mES cells with ds donor [63]
Resveratrol Broad range of biologicalactivities
Increase of HDR in porcine fetal fibroblasts
with ds donor [55]
VPA HDAC inhibitor Increase of HDR in human ESC withds donor [64]
Shown are small molecules that are suggested to directly increase HDR (RS-1), indirectly increasing HDR via
inhibition of NHEJ (i53, STL127705, NU7441, KU-0060648, NU7026, M3814, VE-822, SCR7), regulation of cell cycle
(aphidicolin, mimosin, thymidine, hydroxy urea, nocodazole, ABT-751, XL413) or via undetermined pathways
(L755507, brefeldin A, resveratrol, VPA). Functional aspects of inhibition are described under targets. Observed effects
summarize results for treatment with single inhibitors as reviewed from the specified sources. ATR = ATM-Rad3-
related, DNA-PKcs = DNA-Protein Kinase catalytical subunit, ds = double strand, DSB = Double-Strand Break,
ER = endoplasmic reticulum, ESC = embryonic stem cells, HDAC = histone deacetylases, HDR = Homology
Directed Repair, hiPSC = human induced pluripotent stem cells, hPSC = human pluripotent stem cells, HSPCs
= hematopoietic stem and progenitor cells, mES cells = mouse embryonic stem cells, NHEJ = Non-Homologous
End-Joining, ss = single strand, ssDNA = single-stranded DNA, VPA = valproic acid, 53BP1 = p53-Binding Protein 1.
7. Increase of Homology Directed Repair by Inhibiting Non-Homologous End-Joining
HDR and NHEJ are competitive repair processes in response to DNA DSBs. It was, therefore,
speculated that inhibition of NHEJ might shift the repair pathway choice towards HDR.
7.1. 53BP1
53BP1 recognizes ubiquitylated H2A at DSBs [65], prevents end resection, and thereby promotes
NHEJ [31]. Thus, inhibition of 53BP1 might enable end resection and increase HDR rates. Canny
and colleagues screened a library of ubiquitin variants, aiming to identify a protein that binds 53BP1
and prevents the interaction of 53BP1 with ubiquitylated histones at DSBs. The most promising
ubiquitin variant, i53, was subsequently tested for its use in CRISPR applications. i53 expression
in combination with a double-strand donor increased CRISPR induced insertion of a fluorescent
marker into U2Os cells by nearly 2-fold. Expression of i53 in 53BP1−/− cells did not further increase
effects, demonstrating i53 to act via 53BP1 inhibition. In HEK293T cells, K562 cells and mouse embryo
fibroblasts i53 increased the insertion of fluorescent reporters from double-strand donors into different
gene loci by 1.3-fold, 1.8-fold, and 2.3-fold respectively. It was further shown that i53 expression
increased HDR efficiency with single-strand donors for different target genes in several cell lines [42].
Paulsen and colleagues found that ectopic expression of a dominant-negative 53BP1 variant together
with a single-stranded oligodeoxynucleotide (ssODN) donor significantly increased HDR efficiency
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in 3 out of 4 tested endogenous loci [66]. The fusion of dominant-negative 53BP1 to Cas9 increased
HDR at different gene loci in HEK293T and hematopoietic cell lines on average by 2- to 3-fold [67].
These results thus suggest that inhibiting the binding of 53BP1 to DSBs could favor HDR repair. No low
molecular weight compound, inhibiting 53BP1, has been described up to now.
7.2. Ku70/Ku80
Following a DSB, NHEJ is initiated by the binding of the Ku70/Ku80 heteroduplex to the DNA.
Silencing of Ku70 or Ku80 by small-hairpin RNAs (shRNAs) was found to decrease NHEJ and increase
HDR in transgenic HEK cells in response to CRISPR/Cas9 induced DSB [35]. This effect, however,
might be a gene or cell type-specific or very dependent on the timing of the silencing, since siRNA
knockdown of Ku70 in mouse ES cells showed no significant effect on HDR [34].
In 2016, Weterings and colleagues developed the first specific inhibitor of Ku70/Ku80 heterodimers.
The chemical compound STL127705 inhibits the interaction between the Ku proteins and the DNA
as well as Ku-dependent PKcs activation, both in vitro and in vivo [43]. There is currently no report
where the effect of this inhibitor on the efficiency of HDR mediated genome editing has been evaluated.
7.3. DNA-PKcs
The PI3KKs, ATM, ATR, and DNA-PK, play a central role in the DNA damage response by
phosphorylating various DNA repair factors during NHEJ. Knockdown of DNA-PKcs or its inhibition
by the small molecule inhibitors NU7441 and KU-0060648 were found to reduce NHEJ repair and
increase HDR 2- to 4-fold in HEK293T cells using a plasmid HDR donor or a ssODN donor [44].
The DNA-PKcs inhibitor NU7026 increased ssODN integration efficiency up to 1.6-fold for Cas9
editing in human induced pluripotent stem cells (hiPSC). Inhibitor treatment combined with a two
double nick approach further increased targeted integration by up to 2.5-fold compared to untreated
cells. Combining NU7026 (20 µM), Trichostatin A (0.01 µM), a histone deacetylase inhibitor, MLN4924
(0.5 µM), inhibiting neddylation of CtIP, and NSC15520 (5 µM), an inhibitor of the protein-protein
interaction between the cell cycle checkpoint control proteins p53 or Rad9 and RPA70, in genome
editing applications with Cas9 nickases increased KI efficiencies further [46]. A single treatment with
NU7026 or combinatorial treatment with all four inhibitors showed an HDR promoting effect for
Cpf1 induced DSBs. Except for NU7026, no other inhibitor increased HDR repair of Cas9 induced
DSBs. In contrast to Cas9 Cpf1 produces staggered ends, which might explain potential differences.
CRISPR/Cpf1 editing was also tested in two immortalized cell lines and two primary cell lines. NU7026
was the only inhibitor that showed a consistent increase in HDR efficiency [46].
Despite the successful increase of KI events using DNA-PKcs inhibitors, developing a selective
and potent DNA-PK inhibitor has been a challenge in cancer therapy, due to sequence homologies
between ATM, ATR, and DNA-PK [68]. Older generations of DNA-PKcs inhibitors such as NU7026,
NU7441 or KU-0060648 show less selectivity against ATM and ATR, and/or are less potent compared
to M3814, a new generation of DNA-PKcs inhibitor. In a follow-up study, Riesenberg and colleagues
applied M3814 during genome editing. They were able to boost the effect of NU7026 more than 2-fold
and showed a 4.5-fold increase of HDR in K562 cells. Additionally, they demonstrated the importance
of DNA-PKcs activity for the pathway choice by involving cells with a kinase-deficient mutant of
DNA-PKcs. In these cells a strong increase of HDR to NHEJ repair ratio was observed in 14 different
genes in response to CRISPR/Cas9 introduced DSBs [33].
The use of DNA-PKcs inhibitors did not show an HDR increasing effect in mouse embryonic stem
cells or mouse zygotes [34,47,48] and only a slight increase of HDR in a locus dependent manner using
NU7441 in hiPSC [45]. This indicates effects to be highly dependent on cell-line and locus.
In 2018 a systematic screen of 600 inhibitors to increase Cpf1 mediated knock-in rates in hiPSC
revealed compounds enhancing HDR efficiency by co-electroporation of the donor, guide, and Cpf1
plasmid. VE-822, an ATR inhibitor, was found to increase targeted integration with an optimal
concentration of 1 µM. Further validation showed the inhibitor to increase HDR efficiency by 3-fold
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in combination with an ssODN donor and 5.9-fold with a plasmid donor. The efficiency could be
further increased by combining the ATR inhibitor with a specific inhibitor of checkpoint kinase CHEK1
identified in the same screen [49].
7.4. DNA Ligase IV
An essential step during NHEJ repair is the ligation of the DSB ends, with Ligase IV being the
key enzyme [13,14]. Inhibiting Ligase IV could thus decrease NHEJ and thereby also increase the
HDR/NHEJ ratio. Ligase IV deficient Drosophila melanogaster lines display increased HDR efficiency for
zinc-finger induced DSBs, supporting this hypothesis [32,69].
SCR7 is an inhibitor of Ligase IV, and to a lesser extent also Ligase III, which was first described
as a potential cancer drug. It was hypothesized that inhibiting Ligase IV would inhibit NHEJ and
thereby result in an increased number of unrepaired DSBs, which might cause increased sensitivity of
cancer cells to radio- and chemotherapy. The inhibitor SCR7 was developed in silico to specifically
bind Ligase IV and was demonstrated to interfere with the binding of Ligase IV to Ku-bound DNA
fragments in a cell-free system and several cancer cell lines. In HeLa cells, an extrachromosomal
fluorescent reporter system detected decreased NHEJ efficiencies after SCR7 treatment. In HeLa and
MCF7 cells inhibitor treatment led to an increased number of γ-H2AX foci, indicative of an increased
number of unrepaired DSBs. Importantly, cytotoxicity varied among different cancer cell lines, with
sensitivity being particularly high in an HDR deficient cell-line [50]. This suggests that increased HDR
could partially compensate for impaired NHEJ repair.
Maruyama and colleagues revealed that SCR7 facilitates HDR during CRISPR editing of cultured
cells or mice. SCR7 increased the HDR mediated insertion rates of smaller fragments in A549 lung
carcinoma cells and the melanoma line MelJuSo up to 19-fold and of a larger reporter construct into
a dendritic cell line by approximately 13-fold. While melanoma cells showed a dose-dependent
increase in HDR, 0.01 µM SCR7 was more effective than higher concentrations in epithelial A549 cells.
Interestingly, SCR7 did not decrease the total number of mutations but caused a shift from NHEJ
deletions to HDR insertions. The size distribution of insertions and deletions was not altered by
SCR7 [51].
The insertion of a targeting construct into mouse zygotes was significantly increased by the
co-microinjection of SCR7. Notably, neither viability of zygotes nor the number of live off-spring was
impaired by SCR7 treatment [51], although knockout of Ligase IV in mice showed late embryonic
lethality [70]. As in cell lines, the total number of genetic alterations was hardly changed, but deletions
were reduced and insertions increased. Furthermore, SCR7 increased HDR efficiency in combination
with either a single strand or double strand targeting donor [51].
Singh and colleagues confirmed the HDR promoting effect of SCR7 during CRISPR genome editing
of mouse embryos. In contrast to the previous report, they did not include SCR7 in the microinjection
mix but instead added it to the culture medium during microinjection. Short term culturing in 50 µM
SCR7 overnight did not result in decreased viability of embryos, while prolonged culture showed a
toxic effect. Inhibitor treatment increased the HDR efficiency approximately 10-fold and improved the
HDR/NHEJ ratio [52].
Effects on HDR efficiency in response to SCR7 or Ligase IV knockdown were tested in transgenic
HEK293 cells. A fluorescent reporter system distinguished between HDR mediated repair and NHEJ
induced frameshifts. Increased HDR efficiency for either was detected. In contrast to Maruyama,
decreased NHEJ efficiency was observed [35]. Increased KI rates after SCR7 treatment were moreover
reported for MCF-7 and HCT-116 cells [53], and in rat embryos [54].
While SCR7 was shown to increase HDR mediated integration of dsDNA into fetal porcine
fibroblasts [55], the efficiency to introduce a point mutation by ssODN could not be increased [56].
Estimation of NHEJ and HDR by an extrachromosomal fluorescent reporter construct in H1 cells did
not show a significant difference in HDR or NHEJ efficiency between SCR7 treated and non-treated
controls [57]. Similarly, a small scale study performed on rabbit embryos neither showed effects on
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NHEJ nor HDR [58]. These results suggest that SCR7 is acting in a cell type or gene-specific manner
and might not be useful as a general promoter of HDR during CRISPR genome editing.
8. Increase of Template-Directed Repair by Facilitation of the Homology Directed Repair Pathway
RAD51
Another option to improve the efficiency of HDR mediated genome editing is to directly target
molecules involved in HDR. The binding of helical RAD51 filaments to ssDNA is a crucial step in
HDR. RAD51 overexpression had been reported to promote HDR in Chinese Hamster Ovary (CHO)
fibroblasts [36] and human ES cells [64], while knock-out of RAD51 paralogues resulted in reduced
HDR efficiency in chicken B-lymphocyte DT40 cells [71,72]. Jayathilaka and colleagues performed
an in vitro screen with 10,000 small molecules to find compounds that modulate RAD51 binding
to ssDNA. RS-1 was identified to enhance hRAD51 binding activity in excess of 2-fold and it was
suggested that RS-1 might be useful to improve HDR-based targeted mutagenesis [59]. Indeed, the
Dellaire group later reported that HDR mediated integration of a fluorescent reporter into HEK293A
or U2OS cells was increased 3- to 6-fold after treatment with 10 µM RS-1. At the same time, indel
rates were not altered after inhibitor treatment. It was further shown that the inhibitor can also be
used to increase knock-in (KI) rates after double nicking of the DNA with Cas9 nickases (~4-fold).
However, in another experiment in the same study, RS-1 resulted only in a moderate KI increase of
about 0.3-fold [60]. The reason for this inconsistency was not discussed.
RS-1 treatment was also shown to increase nuclease mediated gene targeting of rabbit embryos.
Using cultured embryos, the Zhang group demonstrated a significant increase of HDR at two different
genetic loci after treatment with 7.5 µM RS-1. This suggests an HDR promoting effect independent of
the target gene. Surprisingly though, a higher concentration of RS-1 (15 µM) did not increase HDR
efficiency but increased blastocyst viability. Additional experiments included implantation and fetal
development of the kits. Knock-in efficiencies were tested for two different genomic loci. In both cases,
the number of embryos with successful KI was increased by ~3-fold, although the total number of
successfully targeted kits was low. Notably, treatment with RS-1 did not reduce the viability of kits.
No obvious alteration of NHEJ mediated indels was observed [58].
Very recently, HDR promoting effects of RS-1 have also been confirmed in bovine embryos.
After microinjection of the CRISPR components and an ssDNA repair template, in vitro fertilized
zygotes were incubated in 7.5 µM RS-1. KI rates were doubled compared to embryos not treated with
RS-1 [61]. Another recent study, however, did not observe an effect with RS-1 [41].
Taken together, RS-1 displayed quite some variation in promoting HDR. More studies are needed
to understand the underlying molecular reason. This knowledge might enable us to predict in which
cell types or for which target genes RS-1 will have a beneficial effect on HDR efficiency.
9. Increase of Homology Directed Repair by Cell Cycle Synchronization
While NHEJ is possible during all phases of the cell cycle, HDR has been described to peak during
S and G2 phases [73]. Performing CRISPR genome editing exclusively at S and G2 phase might thus
increase HDR efficiency.
The Doudna group tried to achieve this goal with the help of cell cycle inhibitors, which stalled the
cell cycle at different stages. Immediately after the release of the cell cycle block, cells were nucleofected
with preassembled Cas9 ribonucleoprotein (RNP) complex. This restricts the editing timeframe
to approximately 24 h after delivery, due to Cas9 degradation. Of four G1/S blockers tested, only
aphidicolin showed an HDR promoting effect both in HEK293T cells and in neonatal fibroblasts. Three
other G1/S inhibitors (mimosin, thymidine, hydroxy urea) increased HDR in neonatal fibroblasts but
surprisingly decreased HDR in HEK293T. Unexpectedly, the G2/M inhibitor nocodazole displayed the
strongest HDR promoting effect in HEK293T cells. As possible explanations, the authors suggest that
timed-RNP delivery into a cell prior to division might effectively target two cells. Additionally, at the
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M-phase the nuclear membrane is broken down, which might facilitate RNP delivery. Nocodazole
synchronization, however, did not increase HDR at the EMX1 gene in neonatal fibroblasts and human
ES cells [62]. Off-target effects of the inhibitors might contribute to unexpected behavior of the cell
cycle inhibitors. An HDR promoting effect by G2/M cell cycle inhibitors was confirmed in human
stem cell lines where nocodazole and ABT-751 enhanced HDR CRISPR genome editing of different
genes. HDR promoting effects were also detected for the repair of DSBs induced by CRISPR N.
meningitides. Strikingly, pluripotent stem cells remained pluripotent during the editing process and
could be differentiated into all three germ layers at a later time point. This demonstrates cell cycle
synchronization to be a robust and easy tool to increase HDR in undifferentiated cell lines [57].
The Corn group performed a screen to identify regulators of HDR with a double-stranded
DNA repair template. Using a reporter system for HDR driven conversion of Blue Fluorescent
Protein (BFP) to Green Fluorescent Protein (GFP) expressed in K562 cells, they identified CDC7 as
a repressor of HDR [41]. Since XL413 had previously been shown to specifically inhibit CDC7 [74]
they then investigated whether this inhibitor might increase HDR efficiency. Indeed, the BFP-to-GFP
reporter system revealed a significant increase in HDR by 1.4-fold and 1.8-fold with single-strand
and double-strand donors respectively. Similar results were achieved for additional gene targets
and the insertion of smaller substitutions as well as bigger transgenes. An HDR promoting effect
for XL413 was also shown for different loci in T cells and HSPCs. Tests in eight additional cell lines
revealed a cell-to-cell variation of inhibitor effect: Four cell lines showed varying effects with an
increase of HDR at some gene loci. The remaining four cell lines never showed an increase in HDR by
inhibitor treatment. Other inhibitors tested in parallel showed either no (RS-1, SCR7) or a variable
effect (L755507, aphidicolin, hydroxy urea) in K562 cells. An increase in HDR by i53 treatment has been
shown to depend on transfection efficiency. Functional analysis of XL413 effects on cell cycle suggests
that arresting cells at early S-phase extends the S/G2/M phase. The inhibitor was thus validated as a
new cell cycle regulator that increases HDR rates [41].
The influence of the cell cycle on HDR has been demonstrated by a genetically engineered
Cas9-geminin fusion protein, which is degraded during the late M or G1 phase but highly expressed
during S/G2/M phase of the cell cycle. HDR efficiencies could be increased by up to 87% compared
to non-modified Cas9. Transient cell-cycle arrest by nocodazole during genome editing with the
transfected Cas9-geminin fusion protein showed an additive effect and resulted in higher HDR levels
than one condition alone [75].
10. Increase of Homology Directed Repair Efficiency by Inhibitors via Undetermined Mechanism
To identify activators of HDR, Yu et al. (2015) screened nearly 4000 small molecules with
pharmacological activity for the increase of HDR mediated integration of GFP into the Nanog locus
in murine ES cells. L755507, a β3-adrenergic receptor agonist, and brefeldin A, an inhibitor of the
intracellular transport from the endoplasmic reticulum (ER) to Golgi, were found to increase HDR 3-
and 2-fold, respectively. L755507 was tested in additional cell types and other targeting loci, for which
also an improved targeting efficiency was observed. An even higher improvement was observed
when a ssODN template was used. How these molecules exert their function on HDR is not clear. For
L755507 a small decrease in NHEJ repair efficiency was detected [63].
Li and colleagues confirmed the effect of L755507 in fetal porcine cells and reported in the same
study that resveratrol promotes HDR. Interestingly, L755507 and in particular resveratrol increased the
expression of several HDR associated genes including RAD51. This correlated in the case of resveratrol
with a strong dose-dependent cytotoxic effect and an increased percentage of cells in the S phase of
the cell cycle. L755507 decreased expression of several NHEJ repair-related genes, but resveratrol
increased their expression [55]. More research is needed to understand the mechanism underlying the
HDR promoting effect of L755507, brefeldin A, and resveratrol.
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In 2012 Takayama and colleagues hypothesized that loosening the chromatin structure at
transcriptionally inactive sites might increase HDR efficiency during CRISPR editing. They screened
an epigenetic library and identified valproic acid (VPA) as an HDR promoting compound in human ES
cells. 24 h pre-treatment with VPA increased HDR efficiency at a transcriptionally active as well as an
inactive site compared to non-treated control cells. It was further demonstrated that acetylation levels
at H3K9, H3K27, and H4K16 were significantly increased at either targeting site [64]. Already earlier it
had been reported that VPA is increasing the frequency of homologous recombination [76].
11. Conclusions
Increasing HDR efficiency in a simple, reproducible manner is one of the most important
requirements to promote gene repair. Improved HDR efficiency will not only facilitate the use of
CRISPR genome editing in therapeutic settings but will also facilitate the use of CRISPR in biomedical
and drug discovery in general, from model generation to the study of disease variants.
Several small molecules have been described that promote HDR either directly or indirectly
by interfering with several steps of NHEJ. However, up to now none of them has become part of
the standard procedure of CRISPR genome editing. This is probably at least partially because the
inhibitors show a considerable cell-to-cell variation of their effects and different efficiencies for specific
genomic sites. The underlying molecular reasons are poorly understood. High throughput screens
or testing of small molecules to enhance HDR are usually performed in immortalized cell lines, such
as HEK293T. These transformed cell lines, modified to be easy to culture and manipulate, can differ
amongst others in their DNA damage response, cell cycle control, or ploidy compared to primary
cells. The effect of a selected small molecule should be evaluated for its functionality in the cell type
of interest. Also, the effect of low molecular weight compounds on CRISPR-related off-target effects,
such as off-target cutting, translocation, and large deletions, must be carefully assessed [77,78].
More detailed knowledge of the DSB repair pathways and the possible role of chromatin
modifications in the regulation of genome editing will be instrumental to overcome the variation or to
predict which inhibitors will work best in a given cell line for a given gene.
High-throughput screens might also be used to identify novel HDR promoting genes and small
molecules. As chromatin packing affects the ratio of NHEJ to HDR [79], chromatin-modifying genes
could be tested for their role in HDR/NHEJ pathway choice.
Broad screens have been carried out with pharmacologically active substances and HDR efficiency
as a readout. However, a systematic analysis of druggable targets in the NHEJ and HDR pathways to
enable screens for low molecular weight substances interfering or promoting specific protein-protein
interactions is still lacking. Such focused screens, ideally also incorporating structural information on
the target protein, could potentially result in more effective HDR promoters than currently available.
Moreover, genetic screens using genome-wide CRISPR-screens can reveal new targets to enhance
gene integration. Once a new target has been identified small molecules can be systematically designed
against the target by modifying their catalytic activity or protein-protein interactions. In addition,
advances in the development of new modalities such as PROteolysis TArgeting Chimeras (ProTacs)
will extend the number of druggable targets [80].
Off-target effects and toxicities could prevent widespread use of HDR promoting small molecules.
This is particularly a problem if different inhibitors are combined in a cocktail. Still, combinatorial
treatment with different HDR promoting small molecules might be a way to overcome cell type and
gene specificities of individual inhibitors. Existing high-throughput systems could be used to test the
effect of different inhibitor combinations and various concentrations.
Alternative strategies based on NHEJ, MMEJ, Prime Editing, or Transposon mediated KI, as well
as Base Editing, may be more efficient in G1 resting cells due to the strict dependency between HDR
and particular phases of the cell cycle [81–85]. Prime Editing and Base Editing directly fuse Cas-
nickases to an effector protein (a DNA deaminase for Base Editing and a Reverse Transcriptase for
Prime Editing). This can overcome the limitations of DSB repair pathway dependency. However, it is
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possible that small molecules interfering with DNA metabolism can further promote the efficiency
of Prime and Base Editing. Taken together, promising small molecule activators of HDR have been
described, but additional work is required to translate this knowledge into a standard protocol for the
broad use in CRISPR genome editing.
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